SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
MEDX 31.18-0.3%Oct 29 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tnsaf who wrote (2145)9/22/2009 10:31:40 AM
From: nigel bates   of 2240
 
>>non-fucosylated antibodies<<

Message 25961700
...Seattle Genetics’ SEA technology comprises modified sugars that inhibit the incorporation of fucose into the carbohydrate chains of monoclonal antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) activity in preclinical models. Significantly, the modified sugars can be readily added to standard cell culture media, without impacting manufacturing processes and while maintaining yields and reproducible product quality....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News